Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.11 USD | -4.20% | -1.91% | -25.27% |
Mar. 27 | North American Morning Briefing : Stocks Edge -2- | DJ |
Mar. 25 | Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2022 | 9.01M | Sales 2023 | 3.31M | Capitalization | 48.89M |
---|---|---|---|---|---|
Net income 2022 | -29M | Net income 2023 | -8M | EV / Sales 2022 | 2.06 x |
Net cash position 2022 | 4.17M | Net cash position 2023 | 15.11M | EV / Sales 2023 | 10.2 x |
P/E ratio 2022 |
-0.74
x | P/E ratio 2023 |
-5.88
x | Employees | 8 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 87.83% |
Latest transcript on Marker Therapeutics, Inc.
1 day | -0.70% | ||
1 week | +1.19% | ||
Current month | -1.40% | ||
1 month | -7.83% | ||
3 months | -0.26% | ||
6 months | +58.80% | ||
Current year | -22.91% |
Managers | Title | Age | Since |
---|---|---|---|
Juan F. Vera
CEO | Chief Executive Officer | 44 | 18-10-16 |
Monic Stuart
CTO | Chief Tech/Sci/R&D Officer | - | - |
Gerald Garrett
CTO | Chief Tech/Sci/R&D Officer | 59 | 19-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 63 | 18-10-16 | |
Steven Elms
BRD | Director/Board Member | 60 | 19-08-05 |
Katharine Knobil
BRD | Director/Board Member | 60 | 21-12-07 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-29 | 4.11 | -4.20% | 12 429 |
24-04-26 | 4.29 | -1.72% | 12,576 |
24-04-25 | 4.365 | -0.80% | 3,381 |
24-04-24 | 4.4 | -0.56% | 9,988 |
24-04-23 | 4.425 | +5.61% | 11,907 |
Delayed Quote Nasdaq, April 29, 2024 at 11:23 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-22.91% | 38.24M | |
+2.60% | 42.75B | |
+47.70% | 41.61B | |
+12.12% | 41.34B | |
-12.36% | 26.59B | |
+8.09% | 25.49B | |
-22.93% | 18.12B | |
+31.36% | 12.24B | |
-1.45% | 11.76B | |
+8.52% | 11B |
- Stock Market
- Equities
- MRKR Stock